New scan and dye aim to spot lung cancer more precisely during surgery

NCT ID NCT07498933

Recruiting now Diagnosis Sponsor: Peking University People's Hospital Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether a special PET/CT scan (FAPI-PET/CT) and a fluorescent dye can better predict how well lung cancer responds to pre-surgery therapy and help surgeons see tumors during operation. 200 adults with stage II-IIIB non-small cell lung cancer will receive the scan and dye before surgery. The goal is to improve accuracy in finding cancer tissue, which could lead to more complete removal of tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: FAPI-PET/CT scan and fluorescent dye
What this could lead to: If successful, this could lead to more accurate tumor detection during lung cancer surgery, helping surgeons remove all cancer cells while sparing healthy tissue.
What could go wrong: This is an early diagnostic study, not a treatment. The imaging technique may not prove more accurate than current methods, and results may not apply to all lung cancer patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEOADJUVANT THERAPY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NEOADJUVANT THERAPY NON-SMALL CELL LUNG CANCER PET/CT

Contacts and locations

Locations

Peking University People's Hospital
RECRUITING

Beijing, Beijing Municipality, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.